AKTX - CIK 0001541157
Akari Therapeutics Plc has filed 710 documents with the SEC between 2012 and 2026. The most frequent type is 6-k (188 filings), alongside the regular cadence of annual reports, quarterly reports, and event disclosures every public company must make. Use the filters to focus on one filing type, or flip the sort to trace the company's history from its earliest paperwork.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Filing | Type | Filed | Period covered |
|---|---|---|---|
| PRE 14A | - | 2026-05-22 | 2026-05-22 |
| Major company event | 8-K | 2026-05-22 | 2026-05-20 |
| RW | - | 2026-05-21 | - |
| Quarterly report | 10-Q | 2026-05-19 | 2026-03-31 |
| NT 10-Q | - | 2026-05-18 | 2026-03-31 |
| IPO registration | S-1 | 2026-05-08 | - |
| EFFECT | - | 2026-04-15 | - |
| POS AM | - | 2026-04-10 | - |
| DRS | - | 2026-04-02 | - |
| F-6/A | - | 2026-03-31 | - |
| Annual report | 10-K | 2026-03-30 | 2025-12-31 |
| Major company event | 8-K | 2026-03-17 | 2026-03-17 |
| Insider trade | 4 | 2026-03-16 | 2025-12-16 |
| SCHEDULE 13D/A | - | 2026-03-04 | - |
| SCHEDULE 13D/A | - | 2026-03-04 | - |
| SCHEDULE 13G/A | - | 2026-03-04 | - |
| Major company event | 8-K | 2026-03-02 | 2026-03-02 |
| Proxy statement | DEF 14A | 2026-02-02 | 2026-02-02 |
| EFFECT | - | 2026-01-29 | - |
| Company correspondence | CORRESP | 2026-01-27 | - |
| SEC correspondence | UPLOAD | 2026-01-27 | - |
| IPO registration | S-1 | 2026-01-23 | - |
| PRE 14A | - | 2026-01-22 | 2026-01-22 |
| Insider trade | 4 | 2025-12-18 | 2025-12-16 |
| Insider trade | 4 | 2025-12-18 | 2025-12-16 |
| Insider trade | 4 | 2025-12-18 | 2025-12-16 |
| Insider trade | 4 | 2025-12-18 | 2025-12-16 |
| Insider trade | 4 | 2025-12-18 | 2025-12-16 |
| Insider trade | 4 | 2025-12-18 | 2025-12-16 |
| Insider trade | 4 | 2025-12-18 | 2025-12-16 |
| Major company event | 8-K | 2025-12-17 | 2025-12-16 |
| Prospectus supplement | 424B5 | 2025-12-17 | - |
| Major company event | 8-K | 2025-12-16 | 2025-12-15 |
| Major company event | 8-K | 2025-12-08 | 2025-12-08 |
| 424B3 | - | 2025-12-05 | - |
| EFFECT | - | 2025-12-02 | - |
| Company correspondence | CORRESP | 2025-12-01 | - |
| Major company event | 8-K | 2025-11-26 | 2025-11-24 |
| Proxy statement | DEF 14A | 2025-11-17 | 2025-11-17 |
| IPO registration | S-1 | 2025-11-17 | - |
| Quarterly report | 10-Q | 2025-11-13 | 2025-09-30 |
| PRE 14A | - | 2025-11-07 | 2025-11-07 |
| Insider trade | 4 | 2025-11-04 | 2025-11-01 |
| Insider trade | 4 | 2025-10-24 | 2025-10-22 |
| New insider ownership | 3 | 2025-10-24 | 2025-10-22 |
| D | - | 2025-10-24 | - |
| Major company event | 8-K | 2025-10-23 | 2025-10-22 |
| Major company event | 8-K | 2025-10-16 | 2025-10-14 |
| Prospectus supplement | 424B5 | 2025-10-16 | - |
| Major company event | 8-K | 2025-10-15 | 2025-10-15 |